Drug Trial Radar · NCT07803965
Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
129
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Nov 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Beijing Sungen Biomedical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an early phase clinical study. Patients who are at high risk of developing severe acute pancreatitis will be screened. Participants will be randomly assigned to receive either SGC001 injection or a placebo injection that contains no active medicine. The study will check how safe and well tolerated SGC001 is, how the body processes this study drug, its biological effects, and whether it may help treat this condition. The study consists of Part A, a dose escalation phase primarily focused on safety and tolerability, and Part B, a dose exploration phase primarily focused on efficacy, both administered as a single add on dose to standard care in patients with predicted severe acute pancreatitis.
Conditions
- Acute Pancreatitis
Interventions
SGC001 injectionDrug
Specification:400mg (10mL) per vial Part A: Dosage and Administration:300mg or 600mg, other dosage determined by the safety review committee (SRC) administered as a single intravenous infusion Infusion Duration:60±10minutes Part B: Based on clinical pharmacokinetic, safety and/or efficacy data obtained from the Part A dose escalation phase, the SRC will select 1 or 2 optimal dose cohorts. Infusion Duration:60±10minutes administered as a single intravenous infusion
PlaceboDrug
Specification: 0mg(10mL)per vial Dosage Administration: 0mg as a single intravenous infusion Infusion Duration:60±10minutes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety Adverse Event (AE)Time frame: Part A Safety: Day 0- Day 85
- Part B: Days alive free of organ failure within 14 days post-randomizationTime frame: Part B: Day 1-Day 15
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
West China Hospital, Sichuan University
Chengdu, China · Not yet recruiting
The Affiliated Hospital of Guizhou Medical University
Guizhou, China · Not yet recruiting
Zhejiang Provincial People's Hospital
Hangzhou, China · Not yet recruiting
The Second Affiliated Hospital of Anhui Medical University
Hefei, China · Not yet recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, China · Not yet recruiting
General Hospital of the Eastern Theater Command of the Chinese People's Liberation Army
Nanjing, China · Recruiting
Li Huili Hospital, Ningbo Medical Center
Ningbo, China · Not yet recruiting
Shanghai General Hospital
Shanghai, China · Not yet recruiting
General Hospital of Northern Theater Command of the Chinese People's Liberation Army
Shenyang, China · Not yet recruiting
The Second Hospital of Hebei Medical University
Shijiazhuang, China · Not yet recruiting
Renmin Hospital of Wuhan University
Wuhan, China · Not yet recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, China · Not yet recruiting
Zhongshan Hospital, Xiamen University
Xiamen, China · Not yet recruiting
Zibo Central Hospital
Zibo, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.